Back to Screener

Healthcare

Akoya Biosciences, Inc.(AKYA)

Live Price

Offline

$1.29

-5.15% today

Window Change

+0.00%

Window

Jun 23, 2025 โ†’ Jul 16, 2025

Market Cap
$64.44M
Revenue Growth
-15.5%
EPS Growth
+21.7%
Dividend Yield
0.0%
Sparse coverage

Historical coverage is still filling in

This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.

Coverage: 17 bars ยท Jun 23, 2025 โ†’ Jul 16, 2025

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Akoya Biosciences, Inc. (AKYA) is a Healthcare stock with a market cap of $64.44M. The stock last traded around $1.29 and up 0.0% across the available one-year price window (Jun 23, 2025 โ†’ Jul 16, 2025). Baseline metrics include revenue growth of -15.5%, EPS growth of +21.7%, a dividend yield of 0.0%. What stands out right now is revenue -15.5%, EPS +21.7%, free cash flow +14.7% with operating margin -50.3% and ROIC -22.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines AKYA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

-15.5% vs +7.6% peer median

Operating Margin

Below sector median

-50.3% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report came in below the EPS bar

2025 was reported on Aug 4, 2025 with an EPS surprise of -22.7%.

The operating picture looks softer than before

Revenue is at -15.5% and EPS is at +21.7%, with operating margin around -50.3%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

AKYA

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

AKYA Max Drawdown

-6.77%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for AKYA and SPY.

Calendar-year return history is still loading or unavailable.
AK

Company Overview

Akoya Biosciences, Inc.

Last Updated
May 7, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
1.7
Price/Book
โ€”

Growth

Revenue
-15.5%
EPS
+21.7%
Free Cash Flow
+14.7%

Profitability

Gross Margin
63.9%
Operating Margin
-50.3%
Net Margin
-62.8%
ROE
-2796.1%
ROIC
-22.7%

Balance Sheet

Debt/Equity
โ€”
Current Ratio
0.61

Earnings Reports

๐Ÿ“… Last reportedAug 4, 2025
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
Aug 4, 25
โœ—
-0.27
Est -0.22
-22.7%
โ€”
Est 18100.0B
โ€”
โ€”
May 12, 25
โœ—
-0.32
Est -0.29
-10.3%
16639.0B
Est 19304.2B
-13.8%
โ€”
Mar 17, 25
โœ—
-0.17
Est -0.15
-13.3%
21344.0B
Est 21341.4B
+0.0%
โ€”
Nov 14, 24
โœ“
-0.18
Est -0.19
+5.3%
18814.0B
Est 21472.9B
-12.4%
โ€”
Aug 5, 24
โ€”
-0.27
Est -0.27
0.0%
23164.0B
Est 23550.0B
-1.6%
โ€”
May 13, 24
โœ—
-0.35
Est -0.30
-16.7%
18350.0B
Est 24280.0B
-24.4%
โ€”
Mar 4, 24
โœ“
-0.22
Est -0.27
+18.5%
26487.0B
Est 25890.0B
+2.3%
โ€”
Nov 8, 23
โœ“
-0.26
Est -0.37
+29.7%
25215.0B
Est 26320.0B
-4.2%
โ€”
Aug 7, 23
โœ—
-0.51
Est -0.44
-15.9%
23521.0B
Est 22440.0B
+4.8%
โ€”
May 8, 23
โœ—
-0.49
Est -0.46
-6.5%
21410.0B
Est 20320.0B
+5.4%
โ€”
Mar 6, 23
โœ—
-0.50
Est -0.41
-21.9%
21219.0B
Est 20465.9B
+3.7%
โ€”
Nov 7, 22
โœ—
-0.47
Est -0.40
-17.5%
18852.0B
Est 17590.7B
+7.2%
โ€”
Aug 8, 22
โœ—
-0.47
Est -0.34
-38.2%
17894.0B
Est 16916.8B
+5.8%
โ€”
May 5, 22
โœ—
-0.44
Est -0.37
-18.9%
16894.0B
Est 14926.8B
+13.2%
โ€”
Mar 14, 22
โœ—
-0.47
Est -0.31
-51.6%
16158.0B
Est 15517.9B
+4.1%
โ€”
Nov 8, 21
โœ—
-0.31
Est -0.28
-10.7%
13476.0B
Est 15650.0B
-13.9%

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks